Clinical experience with moroctocog alfa (AF-CC) in younger paediatric patients with severe haemophilia A: Two open-label studies.
L RusenKaan KavakliJeffrey S BarrettF HuardP RendoJ FuimanJ A BaumannL SmithC AlveyJeremy RuponPublished in: Haemophilia : the official journal of the World Federation of Hemophilia (2018)
Moroctocog alfa (AF-CC) had expected PK findings (lower recovery in young children compared with older children) along with being safe and efficacious in a population of young severe haemophilia A patients.
Keyphrases
- open label
- end stage renal disease
- atrial fibrillation
- ejection fraction
- chronic kidney disease
- newly diagnosed
- early onset
- emergency department
- young adults
- intensive care unit
- replacement therapy
- clinical trial
- middle aged
- prognostic factors
- physical activity
- squamous cell carcinoma
- community dwelling
- phase ii
- smoking cessation
- case control
- phase ii study